INtensity of OVarian Stimualtion and Euploid Embryos

Phase

Condition

Reproductive Health

Treatment

Follitropin-delta (Rekovelle) 20 mcg/day from D1

Follitropin-delta (Rekovelle) 15 mcg/day from D1

Clinical Study ID

NCT06154083

FSD-INO-2023-14

2023-507028-22

Ages 38-42
Female

Study Summary

This randomized trial was designed as a no-inferiority trial aiming to evaluate if the intensity of stimulation (a milder vs a more intense approach) may have an impact on the number of euploid embryos and the morpho kinetic parameters in advanced age women undergoing PGT-A with a PPOS protocol.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Infertile patients with indication for IVF
Undergoing preimplantation genetic screening cycles
AMH >= 1.5 ng/ml and < 3.5 ng/ml (AMH result of up to one year will be valid)
BMI 18.5 - 30 Kg/m2

Exclusion

Exclusion Criteria:

Severe male factor requiring TESE (testicular sperm extraction)
AMH < 1.5 ng/ml or >= 3.5 ng/ml
Administration of any other drug potentially interfering with the treatment
Contraindication for hormonal treatment
Recent history of severe disease requiring regular treatment (clinically significantconcurrent medical condition that could compromise subject safety or interfered withthe trial assessment).
Monogenic disease to be detected with PGT-M

Study Design

Follitropin-delta (Rekovelle) 20 mcg/day from D1

December 12, 2023

May 15, 2026

Connect with a study center

Hospital Universitario Quiron Dexeus
Barcelona, 08028
Spain
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.